

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/024,460	0 12/17/2001		Alan Berry	3161-18-C1-1	4571
22442	7590	11/18/2004		EXAM	INER
SHERIDA 1560 BROA		PC	FRONDA, CHRISTIAN L		
SUITE 1200			ART UNIT	PAPER NUMBER	
DENVER,	CO 80202	2	1652		
				DATE MAILED: 11/18/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		10/024,460	BERRY ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Christian L Fronda	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE - Exte after - If the - If NC - Failt Any	ORTENED STATUTORY PERIOD FOR F MAILING DATE OF THIS COMMUNICAT insions of time may be available under the provisions of 37 (c SIX (6) MONTHS from the mailing date of this communicati e period for reply specified above is less than thirty (30) days of period for reply is specified above, the maximum statutory are to reply within the set or extended period for reply will, by reply received by the Office later than three months after the ed patent term adjustment. See 37 CFR 1.704(b).	ION.  CFR 1.136(a). In no event, however, may on.  s, a reply within the statutory minimum of period will apply and will expire SIX (6) Means the application to become	a reply be timely filed  hirty (30) days will be considered timely.  ONTHS from the mailing date of this communication.  ARANDONED (35 U.S.C. & 133)				
Status							
1)[	Responsive to communication(s) filed on						
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠	This action is non-final.					
3)□	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims						
5) 6) 7)	Claim(s) 61-80 is/are pending in the appli 4a) Of the above claim(s) is/are wit Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 61-80 are subject to restriction a	hdrawn from consideration.					
Applicati	on Papers						
9)[	The specification is objected to by the Exa	miner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
	inder 35 U.S.C. § 119						
12) [ ] a)[	Acknowledgment is made of a claim for for All b) Some * c) None of:  1. Certified copies of the priority docur 2. Certified copies of the priority docur 3. Copies of the certified copies of the application from the International But ee the attached detailed Office action for a	ments have been received. ments have been received in priority documents have bee ureau (PCT Rule 17.2(a)).	Application No n received in this National Stage				
Affaahma	(6)						
Attachment 1) 🏻 Notice	(s) e of References Cited (PTO-892)	4) Intention	Summary (PTO-413)				
2)	e of Draftsperson's Patent Drawing Review (PTO-948 nation Disclosure Statement(s) (PTO-1449 or PTO/SI No(s)/Mail Date	B) Paper No	(s)/Mail Date Informal Patent Application (PTO-152)				

Art Unit: 1652

## **DETAILED ACTION**

## Election/Restriction

- 1. The previous restriction requirement has been withdrawn in favor of the instant restriction requirement.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claim(s) 61-72, drawn to a method to produce glucosamine by culturing a microorganism transformed with a recombinant nucleic acid comprising a nucleic acid encoding glucosamine-6-phosphate synthase and a *lac* promoter, classified in class 435, subclass 84.
  - II. Claim(s) 73-77, drawn to a method to produce glucosamine by culturing a microorganism that has at least one genetic modification that increases activity of glucosamine-6-phosphate synthase and at least one additional genetic modification that increases activity of a phosphatase, classified in class 435, subclass 84.
  - III. Claim(s) 78-80, drawn to a method to produce glucosamine by culturing a microorganism that has at least one genetic modification that increases activity of glucosamine-6-phosphate synthase, classified in class 435, subclass 84.
- 3. The inventions are distinct, each from the other because of the following reasons:
  Inventions of Groups I-III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The processes of Groups I-III are distinct both physically and functionally; require different process steps, reagents, and parameters; have different purposes; and produce different products.

A search of all the inventions in the patent literature and the non-patent literature cannot be made without serious burden because the inventions require separate searches that have different limits, boundaries, scope, and subject matter. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Art Unit: 1652

4. Claim 70 of the invention of Group I recite patentably distinct proteins that have different biological functions and structures. If the invention of Group I is elected, then Applicants are required under 35 U.S.C. 121 to elect a single disclosed protein in claim 70 even though this requirement is traversed.

Should applicant traverse on the ground that the proteins are not patentably distinct, applicants should submit evidence or identify such evidence now of record showing the proteins to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.
- 7. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christian L. Fronda

Muslin I Tronde

Art Unit 1652